Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1b/2a Study of SLC-391, an AXL Inhibitor, in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05860296 is registered in ClinicalTrials.gov with SignalChem Lifesciences Corporation as lead sponsor.

NCT NCT05860296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05860296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1b/2a Study of SLC-391, an AXL Inhibitor, in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
SignalChem Lifesciences Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2023
Completion date
December 1, 2025
Enrollment
36 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer metastatic, lung cancer stage iv, lung cancer, nonsmall cell